Search - tctmd.com

Displaying 441 - 460 of 465

Sort: Relevancy | Date

News Daily News

Las Sociedades Recomiendan los Requisitos para el Programa TAVR

L.A. McKeown

March 06, 2012

News Daily News

PARTNER: TAVR Cost-Effectiveness Evaluated in Inoperable Patients

Leah Lawrence

February 09, 2012

News Daily News

Interventional Issues Featured in AHA/ASA ‘Top 10’ Research Reports of 2011

February 07, 2012

News Daily News

Fewer Vascular Complications as TAVR Evolves

Caitlin E. Cox

January 10, 2012

News Conference News

PARTNER Cohort B: TAVR Remains Superior to Standard Therapy at 2 Years

November 09, 2011

News Industry News

CoreValve gets CE Mark, FDA grants PARTNER II extension

November 07, 2011

News Industry News

Edwards Receives FDA Approval to Expand U.S. Clinical Trial of Next-Generation Transcatheter Valve

November 06, 2011

News Conference News

Comprehensive French TAVI Registry Shows Promising Results

August 31, 2011

News Daily News

TAVI Appears Safe for Patients with Small Annuli

August 22, 2011

News Industry News

REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation

August 18, 2011

News Industry News

First Patients Treated in TriVascular's OVATION Post Market Registry

July 26, 2011

News Daily News

SOURCE Registry Data Published: TAVI Stays Strong at 1 Year

Caitlin E. Cox

July 15, 2011

News Daily News

PARTNER Cohort A Published: Surgical Candidates Obtain Similar 1-Year Survival with TAVI, Surgery

L.A. McKeown

June 07, 2011

News Industry News

STENTYS Joins Stent for Life Initiative to Expand Optimal Heart Attack Treatment Across Europe

May 18, 2011

News Daily News

Single-Center Experience Shows Evolution of CoreValve Procedure Over Time

Jason Kahn

April 18, 2011

News Conference News

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

Caitlin E. Cox

April 08, 2011

News Industry News

REMEDIAL II Trial of PLC's RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care

April 04, 2011

News Industry News

Edwards Lifesciences Expands Treatable Patient Population With European Approval of Larger Transcatheter Valve

February 23, 2011

News Daily News

Different Factors Linked to Early, Late Mortality with CoreValve TAVI

L.A. McKeown

January 13, 2011

News Daily News

NEJM Letters Take on PARTNER Trial

Caitlin E. Cox

January 11, 2011

Advertisement

Las Sociedades Recomiendan los Requisitos para el Programa TAVR

PARTNER: TAVR Cost-Effectiveness Evaluated in Inoperable Patients

Interventional Issues Featured in AHA/ASA ‘Top 10’ Research Reports of 2011

Fewer Vascular Complications as TAVR Evolves

PARTNER Cohort B: TAVR Remains Superior to Standard Therapy at 2 Years

CoreValve gets CE Mark, FDA grants PARTNER II extension

Edwards Receives FDA Approval to Expand U.S. Clinical Trial of Next-Generation Transcatheter Valve

Comprehensive French TAVI Registry Shows Promising Results

TAVI Appears Safe for Patients with Small Annuli

REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation

First Patients Treated in TriVascular's OVATION Post Market Registry

SOURCE Registry Data Published: TAVI Stays Strong at 1 Year

PARTNER Cohort A Published: Surgical Candidates Obtain Similar 1-Year Survival with TAVI, Surgery

STENTYS Joins Stent for Life Initiative to Expand Optimal Heart Attack Treatment Across Europe

Single-Center Experience Shows Evolution of CoreValve Procedure Over Time

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

REMEDIAL II Trial of PLC's RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care

Edwards Lifesciences Expands Treatable Patient Population With European Approval of Larger Transcatheter Valve

Different Factors Linked to Early, Late Mortality with CoreValve TAVI

NEJM Letters Take on PARTNER Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content